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ABSTRACT 20 
Background: Nitric oxide prevents hypertension yet enhances proximal tubule Na+ reabsorption. 21 
Nitric oxide synthase is inhibited by asymmetric dimethylarginine (ADMA) that is metabolized 22 
by dimethylarginine dimethylaminohydrolase (DDAH) whose type 1 isoform is expressed 23 
abundantly in the PT. 24 
Hypothesis: That ADMA metabolized by DDAH-1 inhibits fluid reabsorbtion (Jv) by the 25 
proximal tubule.  26 
Methods: S2 segments of the PT were microperfused between blocks in vivo to assess Jv in 27 
anesthetized rats. 28 
Results: Compared to vehicle, microperfusion of ADMA or N ω -nitro-l-arginine methyl ester 29 
(L-NAME) into the proximal tubule reduced Jv dose-dependently. At 10-4 mol·l-1 both reduced 30 
Jv by ~ 40% (vehicle: 3.2 ± 0.7 vs ADMA: 2.1 ± 0.5; P<0.01; vs L-NAME: 1.9 ± 0.4 nl∙min-31 
1∙mm-1; P<0.01; n=10). Selective inhibition of DDAH-1 in rats with intravenous L-257 (60 32 
mg·kg-1) given 2 hours before and L-257 (10-5 mol∙l-1) perfused into the proximal tubule for 5 33 
minutes reduced Jv by 32±4% (vehicle: 3.2 ±  0.5 vs L-257: 2.2 ± 0.5 nl·min-1·mm-1; P<0.01) 34 
and increased plasma ADMA by ≃ 50% (Vehicle: 0.46 ± 0.03 vs L-257: 0.67 ± 0.03 µmol∙l-1; P 35 
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< 0.0001) without changing plasma symmetric dimethylarginine. Compared to non-targeted 36 
control small interference RNA, knock down of DDAH-1 in mice by 60% with targeted siRNA 37 
reduced Jv by 29±5% (nontargeted SiRNA: 2.8 ± 0.20 vs DDAH-1 knockdown: 1.9 ± 0.31 38 
nl·min-1·mm-1; P<0.05). 39 
Conclusions: Fluid reabsorption in the proximal tubule is reduced by tubular ADMA or by 40 
blocking its metabolism by DDAH-1. L-257 is a novel regulator of proximal tubule fluid 41 
reabsorption.  42 
  43 
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INTRODUCTION 44 
Nitric oxide (NO) relaxes blood vessels, prevents salt sensitivity (23), reduces 45 
sympathetic nervous system tone (11), reduces or prevents hypertension and protects blood 46 
vessels, the heart, the kidney and other organs from hypertensive damage (26). Indeed, a reduced 47 
renal expression of nitric oxide synthase (NOS)1 has been related to progression of kidney 48 
disease in a wide range of animal models (3). NO causes vasodilation of renal afferent arterioles 49 
(13), inhibits the vasoconstrictive tubuloglomerular feedback response (24) and inhibits Na+ 50 
reabsorption in the thick ascending limb of the loop of Henle and the collecting ducts (7). 51 
Although, blockade of NOS has variable effects on Na+ excretion, genetic deletion of NOS1 and 52 
3 sharply reduce the reabsorption of fluid in the mouse proximal tubule in most (21), but not all 53 
studies (18). The differences may relate to the effects of the NOS 1 alpha and NOS 1 beta splice 54 
variants (14). 55 
Asymmetric dimethylarginine (ADMA) is a cellular and circulating inhibitor of NOS (2) 56 
that is metabolized by dimethylaginine dimethylaminohydrolase (DDAH) whose type 1 isoform 57 
is heavily expressed in the proximal tubule (19). Although the function of DDAH in the kidney 58 
has not been studied, there are compelling clinical data linking it to CKD. Thus, circulating 59 
levels of ADMA have been considered to be a uremic toxin and predict the progression of CKD 60 
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(12, 28). However, activating polymorphism of DDAH-1 (5) that reduce circulating ADMA are 61 
associated with protection from progression of CKD (5) and salt sensitivity (6). Thus, DDAH-62 
1/ADMA/NO in the kidney may have effects independent of circulating ADMA. We tested the 63 
hypothesis that DDAH-1 regulates proximal tubule fluid reabsorption by regulating ADMA. 64 
First, rat renal proximal tubules were perfused with artificial tubular fluid (ATF) with graded 65 
addition of Nw-nito-l-arginine methyl ester (L-NAME) to inhibit nitric oxide synthase isoforms 66 
or ADMA. Second, the effects of DDAH-1 were tested in rats administered with L-257 that is a 67 
specific DDAH-1 inhibitor (22). The findings were extended to a study in the mouse by gene 68 
silencing of DDAH-1 (19).   69 
MATERIALS AND METHODS  70 
Animals:  71 
The experiments were conducted under protocols approved by the Georgetown 72 
University Animal Care and Use Committee and performed according to the National Institutes 73 
of Health guidelines for the conduct of experiments in animals. Male Sprague-Dawley rats and 74 
C57Bl/6 mice were housed in cages kept in temperature-controlled units (25°C) with a 12 h 75 
light/dark cycle and maintained on a standard chow with free access to food and water.  76 
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Surgical Preparation: 77 
Rats were prepared for renal micropuncture under anesthesia with thiobarbital (Inactin, 78 
80 mg.kg-1 IP; Research Biochemicals, Inc.) and infused with isotonic saline containing1% 79 
bovine serum albumin (Sigma Chemical St. Louis, MO) at 1.5ml·hr-1 to maintain euvolemia as 80 
described (24).  81 
Mice were anesthetized by with isoflurane (1.0% in room air, delivered by a pump, 82 
Univenter, Malta) and prepared for micropuncture as described (1, 4). Cannulae were placed in a 83 
jugular vein for infusion of isotonic saline containing 1.5% bovine serum albumin at 0.35 ml·hr-1 84 
to maintain euvolemia (4). In both rats and mice, a femoral artery was cannulated for recording 85 
of mean arterial pressure (MAP; Powerlab, AD Instruments Inc), the left ureter was cannulated 86 
to collect urine from the left experimental kidney that was exposed by a flank incision and 87 
stabilized in a Lucite cup (Vestavia Scientific, Birmingham, AL) for micropuncture (1, 4, 24). 88 
The study commenced 60 minutes after surgery. 89 
Microperfusion of proximal tubules (PTs) of rats and mice: 90 
As described previously for rats (24) and mice (1, 4), a surface proximal tubule loop (S2 91 
segment) was identified by injection from a “finding” pipette (8-µm outer diameter) containing 92 
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artificial tubule fluid stained with the Fast Green FCF dye (Sigma, 0.1%). An immobile grease 93 
block (Apiezon T, Manchester, UK) was injected into the tubule at the puncture site to stop 94 
tubular fluid flow. A perfusion pipette (8-to 10-µm outer diameter) was inserted immediately 95 
downstream from the block. The perfusion pipette was filled with artificial tubular fluid 96 
containing (mmol.l-1): 125 NaCl, 20 NaHCO3, 5 KCl, 1 MgSO4, 2 CaCl2, 1 NaH2PO4, 5 Glucose, 97 
4 urea) and [14C]- inulin. It was connected to a calibrated nanoliter perfusion pump (Vestavia 98 
Scientific, Birmingham, AL) to perfuse the segment of the proximal tubule for 2 to 4 minutes 99 
before timed fluid collections. The collections were made at a downstream site with a 100 
micropipette (8-to 10µm outer diameter) after placement of a column of oil to block downstream 101 
flow. The samples were collected for 4 minutes and transferred into a constant-bore capillary 102 
tube whose length was measured with a micrometer to calculate the tubular fluid volume. 103 
Thereafter, the samples were injected into scintillation fluid and the 14C activity counted. 104 
Collected samples with <95% and >105% of microperfused [14C]- inulin were discarded. The 105 
amount of microperfused inulin was estimated by the average of 14C-activity in 3 samples 106 
perfused into a vial over 4 minutes. To determine the lengths of the perfused segments, tubules 107 
were filled with high-viscosity microfil (Flow Tech, Inc.), the kidney was partially digested in 108 
20% NaOH, and the length of the cast was measured under a dissecting microscope. The Jv was 109 
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calculated by the difference in the rate of fluid perfusion and the rate of fluid collection factored 110 
by the length of the perfused nephron segment (1, 4, 24). 111 
 Construction and administration of small interference RNAs (siRNAs):  112 
These studies were performed in mice.  RNAi duplexes of 21 nucleotides targeting the 113 
coding region of DDAH-1 (siDDAH-1) (Qiagen) were validated in vitro as described previously 114 
(19). The target site in the mouse DDAH-1 cDNA (GenBank accession no. NM_026993) of the 115 
construct selected was 673 to 693 (TGGCCGATTCTTTGCATTTAA). The non-silencing 116 
control SiRNA (catalogue # 1027280; Qiuagen) had no homology to any sequence in the 117 
mammalian genome. Under brief anesthesia with 1% to 2% isoflurane, cannulae were inserted 118 
into the femoral vein of the mouse for rapid injection of 25ug siRNA constructs diluted in 1 ml 119 
of TransIT-QR Hydrodynamic Delivery Solution (Mirus: ZL) injected within 5 seconds. The 120 
effects of this hydrodynamic DDAH-1 silencing were assessed by RNA analysis in the harvested 121 
kidney cortex after 48 hours. 122 
Protocols: 123 
Protocol 1. Microperfusion of ADMA or L-NAME into the proximal tubule of rats: 124 
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ADMA or L-NAME were dissolved in artificial tubular fluid at 10-7 M to 10-4 mol·l-1 and 125 
perfused into a rat proximal tubule between blocks. Alternate tubules were perfused with 126 
artificial tubular fluid + vehicle or ADMA or L-NAME.  127 
Protocol 2. Blockade of DDAH-1 with L-257 in rats: 128 
  For each series, Jv was measured in a perfused proximal tubule of a rat after 129 
administration of vehicle or L-257. The optimal method for delivery of L-257 was assessed from 130 
three protocols:  131 
A. Proximal tubule perfusion of L-257 (10-5mol∙l-1) or vehicle; 132 
B. IV injection of L-257 (60 mg.kg-1) or vehicle two hours previous, followed by tubular 133 
perfusion with vehicle, and  134 
C. IV injection of L-257 or vehicle two hours previous followed by tubular perfusion with L-257 135 
or vehicle. 136 
In separate groups, blood was collected for two hours following bolus IV injection of 137 
vehicle or L-257 for measurements of plasma ADMA and symmetric dimethylarginine (SDMA) 138 
with a fully validated gas chromatography- mass spectrometry method (GC/MS) and quantitated 139 
relative to deuterated standards (17).  140 
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 141 
Protocol 3. Gene silencing of DDAH-1 in mice: 142 
The Jv of the perfused proximal tubule of C57/BL6 mice was assessed after iv injection 48 143 
hours previously of siRNA directed to DDAH-1 or non-targeted control siRNA, as described in 144 
detail previously (19). The kidney cortex was harvested to measure mRNA expression of DDAH-145 
1. 146 
RNA extraction, cDNA synthesis, and real-time PCR:  147 
RNA was extracted from harvested tissues using a RNeasy Mini Kit (Qiagen ZL). The 148 
cDNA was synthesized using iScriptTM  cDNA Synthesis kit (Biorad ZL) . The gene expression 149 
for DDAH-1 was assessed with real-time PCR (StepOnePlus Real-time PCR System, ABI ZL), 150 
using a FAM (6-carboxy-fluorescine dye)-labeled DDAH-1 Taqman probe assay 151 
(Mm01319453_ml, ABI) multiplexed with a VIC (fluorescine dye) –labeled 18S control probe. 152 
Relative amounts of mRNA, normalized by 18S rRNA, were calculated from threshold cycle 153 
numbers (CT, ie, 2- ΔΔCT).  154 
Drugs:  155 
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ADMA (NG, NG – dimethylarginine dihydrochloride) and L-NAME (Nω-nitro-L- arginine 156 
methyl ester hydrochloride) were purchased from Sigma Chemical (St. Louis, MO). L-257 is a 157 
fully validated DDAH-1 inhibitor that was synthesized in the laboratory of James Leiper of the 158 
MRC Clinical Sciences Center, London (22).  159 
Statistical Analysis: 160 
Data are presented as means ± SE. The significance of differences within and between 161 
groups was evaluated using ANOVA followed by a Fisher’s post hoc test where appropriate. 162 
Results were considered significant at P<0.05.  163 
RESULTS 164 
Proximal tubule fluid reabsorption in rats during luminal microperfusion of L-NAME or 165 
ADMA: 166 
Microperfusion of L-NAME or ADMA reduced Jv similarly and dose-dependently (Figure 167 
1). At the maximum dose tested of 10-4 mol·l-1, ADMA reduced Jv by 41 ± 5% (Vehicle: 3.3 ± 0.5 168 
vs ADMA: 1.9±0.4 nl·min-1·mm-1, P<0.01; n=10 tubules) and L-NAME by 38 ± 6% (Vehicle: 3.3 169 
± 0.5 vs L-NAME: 2.1 ± 0.5 nl·min-1·mm-1; P<0.01, n=10 tubules).  170 
Proximal tubule fluid reabsorption in rats after inhibition of DDAH-1 with L-257: 171 
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L-257 delivered by IV injection 2 hours prior to experimentation and by direct perfusion 172 
of the proximal tubule reduced the Jv by 32 ± 4% (Vehicle: 3.2 ± 0.4 vs L-257: 2.2 ± 0.5 nl∙min-173 
1∙mm-1; P<0.01; n=8 tubules). (Figure 2). Direct tubular perfusion of L-257 or sole IV 174 
administration of L-257 did not change Jv consistently (data not shown). The IV administration of 175 
L-257 to rats 2 hours previously increased plasma ADMA by 50% (vehicle: 0.46 ± 0.03 vs L-257: 176 
0.67 ± 0.03 µmol·l-1; P< 0.0001) without changing SDMA (Figure 3). 177 
Proximal tubule fluid reabsorption in mice after knockdown of DDAH-1 with siRNA: 178 
Injection of siRNA for DDAH-1 in rats produced quite variable knockdown of DDAH-1 179 
mRNA in the kidney whereas the knockdown in mice was more consistent. Therefore, mice were 180 
selected for this protocol. Rapid bolus IV injections of siRNA directed to DDAH-1, compared to 181 
non-targeted siRNA, given 48 hours prior to experimentation to mice reduced the expression of 182 
mRNA to DDAH-1 in the renal cortex by 55 ± 5%  and reduced Jv in the PT by 43 ± 5% (siControl: 183 
2.3 ± 0.4 vs siDDAH-1: 1.3 ± 0.3 nl∙min-1∙mm-1; P<0.01, n=6) (Figure 4). 184 
DISCUSSION 185 
We confirm that L-257 is an effective inhibitor of DDAH-1 and increases plasma levels 186 
of ADMA by 50% (22). The main new findings are that ADMA is as effective as L-NAME in 187 
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reducing Jv of the rat perfused proximal tubule. Maximal concentrations of each drug reduced Jv 188 
by ≃ 40% that was similar to the reduction of Jv of 32% following pharmacological inhibition of 189 
DDAH-1 with L-257 in rats or reduction of Jv of 43% following gene silencing of DDAH-1 in 190 
mice.  191 
ADMA is produced by hydrolysis of methyl arginine moieties in proteins after 192 
methylation by protein arginine methyl transferases (PRMT) (15). Its plasma levels are primarily 193 
regulated by metabolism by DDAH (2, 10). ADMA also can be metabolized by alanine-194 
gluyoxilate amino transferase II (AGXT II) (2). However, the finding that the proximal tubule 195 
fluid reabsorption was inhibited similarly by direct microperfusion of ADMA or by 196 
pharmacological inhibition of ADMA metabolism by DDAH-1 or silencing of the DDAH-1 gene 197 
demonstrates the importance of DDAH-1 for regulation of ADMA in the proximal tubule.  198 
DDAH-1 is heavily expressed in the liver and the proximal tubule (9, 16). Measurements 199 
of ADMA extraction across organs in vivo has shown that the kidney and the liver are the prime 200 
sites for clearance of plasma ADMA (2, 10, 15). The large increase in plasma ADMA after 201 
knockdown of DDAH-1 in this study is consistent with these findings. SDMA is not metabolized 202 
by DDAH (2). Therefore, the finding that plasma levels of ADMA were increased, but SDMA 203 
were unchanged, after L-257 provides further evidence of the specific effect of L-257 to inhibit 204 
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DDAH (22). The failure of L-257 to reduce Jv significantly when perfused directly into the PT 205 
may relate to the limited time of tubular exposure of ~ 5 minutes. This may have been 206 
insufficient for ADMA to accumulate effectively after inhibition of its metabolism by blocking 207 
DDAH-1. In contrast, DDAH-2 is expressed in the vascular endothelium and the distal nephron 208 
and macula densa of the kidney. Unlike DDAH-1, knockdown of DDAH-2 in the rat impairs 209 
endothelial function and reduces the expression of endothelial NOS but does not change plasma 210 
levels of ADMA (19). However, the DDAH-1 knockout mouse has endothelial dysfunction (27), 211 
suggesting differences between rats and mice in the specific roles of the DDAH isoforms. In this 212 
study, DDAH-1 was inhibited by two distinct means (pharmacological and gene knockdown) in 213 
rats and in mice. The similar effects of these to reduce proximal tubule fluid reabsorption by 30 214 
to 45% suggest an important role for DDAH-1 in the proximal tubules of both species. The 215 
expression of DDAH-1, and consequently the plasma and tissue levels of ADMA, are regulated 216 
by reactive oxygen species both in vitro (8) and in vivo (20, 25) and thereby have been linked to 217 
pathophysiology of hypertension and CKD (25).  218 
We acknowledge some limitations of our study. DDAH-1 was blocked 219 
pharmacologically in rats and by gene knockout in mice. However, the similar effects on 220 
proximal fluid reabsorption suggest no major species difference. Inhibition or silencing of 221 
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DDAH-1 will have systemic effects that could influence proximal tubule reabsorption. However, 222 
DDAH-1 silencing over 2 hours does not change BP significantly (19). Moreover, ADMA 223 
perfused into the nephron had a similar effect to reduce proximal tubule reabsorption as did 224 
systemic inhibition of its metabolism by DDAH-1 blockade or gene knockdown. 225 
 In conclusion, ADMA and its metabolism by DDAH-1, are important determinants of 226 
proximal tubule fluid reabsorption in rats and mice. 227 
PERSPECTIVE 228 
Luminal ADMA inhibited rat proximal tubule fluid reabsorption at 10-7 mol·l-1 which is 229 
at the plasma level of ADMA of 3×10-7 mol·l-1 recorded in this study. A 55% knockdown of 230 
DDAH-1 in the mouse reduced proximal tubule reabsorption significantly. This reduction in 231 
DDAH-1 expression is equivalent to that reported in earlier studies in rats infused with 232 
angiotensin II that was attributed to reactive oxygen species (8, 20, 25). Thus, these findings 233 
establish ADMA as a physiological inhibitor of proximal tubule reabsorption and DDAH-1 as an 234 
important physiological regulator of proximal tubule function in vivo in rats and mice. Moreover, 235 
DDAH-1 and ADMA may contribute to the pathophysiology of hypertension and conditions 236 
associated with oxidative stress.  237 
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FIGURE LEGENDS 326 
Figure 1  327 
L-NAME and ADMA inhibit fluid reabsorption (Jv) in the rat perfused proximal tubule in vivo 328 
during microperfusion and recollection of artificial tubular fluid +Vehicle; (open circle), + L-329 
NAME (solid triangles and continuous lines) or + ADMA (solid squares and broken lines). 330 
Compared with ATF + Vehicle *, P < 0.05. 331 
Figure 2 332 
Blockade of DDAH-1 with L-257 in the rat reduces absolute proximal tubule fluid reabsorption 333 
(Jv) 2 hours after IV injection of L-257 (60 mg·kg-1) and during tubule perfusion of L-257 (10-5 334 
mol·l-1; solid boxes) compared to corresponding administration of vehicle (open boxes)  335 
Figure 3 336 
Intravenous injection of L-257 increases asymmetric dimethylarginine (ADMA) selectively. 337 
Plasma levels of ADMA or symmetric dimethylarginine (SDMA) two hours after IV injection of 338 
vehicle (open boxes) or L-257 (solid boxes).  339 
Figure 4 340 
Knockdown of DDAH-1 with siRNA reduces absolute proximal tubule fluid reabsorption (Jv) in 341 
the mouse proximal tubules 48 hours after IV injections of siRNA to DDAH-1 (solid boxes) 342 
compared to non-targeted siRNA (open boxes).  343 
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